[1]tncd_chap-02-cancer-estomac_2017-10-10.pdf [Internet]. [cited 2017 Nov 26]. Available from : http://www.snfge.org/sites/default/files/SNFGE/TNCD/tncd_chap-02-cancer-estomac_2017-10-10.pdf.
[2]Hanna N., Johnson D., Temin S. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35:3484-3515.
[3]Zhang Q., Zhao Y.-P., Liao Q. Associations between gene polymorphisms of thymidylate synthase with its protein expression and chemosensitivity to 5-fluorouracil in pancreatic carcinoma cells. Chin Med J (Engl). 2011;124:262-267.
[4]Janjigian Y.Y., Bendell J.C., Calvo E. CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). J Clin Oncol. 2016;34:4010. Suppl. 15
[5]Muro K., Chung H.C., Shankaran V. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012) : a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17:717-726.
[7]Wilke H., Muro K., Van Cutsem E. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224-1235.
[8]Comprehensive molecular characterization of gastric adenocarcinoma. - PubMed - NCBI [Internet]. [cited 2017 Nov 26]. Available from : https ://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/?term=molecular+classification+gastric+cancer+Nature+2014.
[9]Le D.T., Uram J.N., Wang H. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372:2509-2520.
[10]Lin S.J., Gagnon-Bartsch J.A., Tan I.B. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut. 2015;64:1721-1731.